JP2014525925A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525925A5
JP2014525925A5 JP2014525432A JP2014525432A JP2014525925A5 JP 2014525925 A5 JP2014525925 A5 JP 2014525925A5 JP 2014525432 A JP2014525432 A JP 2014525432A JP 2014525432 A JP2014525432 A JP 2014525432A JP 2014525925 A5 JP2014525925 A5 JP 2014525925A5
Authority
JP
Japan
Prior art keywords
sequence
seq
region
combination
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014525432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525925A (ja
JP6114273B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/065904 external-priority patent/WO2013024095A1/en
Publication of JP2014525925A publication Critical patent/JP2014525925A/ja
Publication of JP2014525925A5 publication Critical patent/JP2014525925A5/ja
Application granted granted Critical
Publication of JP6114273B2 publication Critical patent/JP6114273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014525432A 2011-08-16 2012-08-14 抗−ｃｄ１９抗体とプリン類似体の併用治療 Active JP6114273B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660.5 2011-08-16
EP11177660 2011-08-16
US61/523,862 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (3)

Publication Number Publication Date
JP2014525925A JP2014525925A (ja) 2014-10-02
JP2014525925A5 true JP2014525925A5 (https=) 2015-10-01
JP6114273B2 JP6114273B2 (ja) 2017-04-12

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525432A Active JP6114273B2 (ja) 2011-08-16 2012-08-14 抗−ｃｄ１９抗体とプリン類似体の併用治療

Country Status (25)

Country Link
US (3) US20140227277A1 (https=)
EP (2) EP4083071A3 (https=)
JP (1) JP6114273B2 (https=)
KR (3) KR20200060779A (https=)
CN (1) CN103703027B (https=)
AU (1) AU2012296905B2 (https=)
BR (1) BR112013033916B1 (https=)
CA (1) CA2841738C (https=)
CY (1) CY1125148T1 (https=)
DK (1) DK2744826T3 (https=)
ES (1) ES2909720T3 (https=)
HR (1) HRP20220224T1 (https=)
HU (1) HUE058855T2 (https=)
IL (1) IL230295B (https=)
LT (1) LT2744826T (https=)
MX (1) MX353589B (https=)
PL (1) PL2744826T3 (https=)
PT (1) PT2744826T (https=)
RS (1) RS63121B1 (https=)
RU (1) RU2664462C9 (https=)
SG (1) SG10201606788VA (https=)
SI (1) SI2744826T1 (https=)
SM (1) SMT202200160T1 (https=)
WO (1) WO2013024095A1 (https=)
ZA (1) ZA201401835B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) * 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
RS62155B1 (sr) * 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例
CN121729431A (zh) 2023-07-13 2026-03-24 克里斯蒂安-阿尔伯特基尔大学 人源化抗cd7抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) * 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Similar Documents

Publication Publication Date Title
JP6114273B2 (ja) 抗−ｃｄ１９抗体とプリン類似体の併用治療
US20240366756A1 (en) Combinations and uses thereof
JP2014525925A5 (https=)
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
JP2014525926A5 (https=)
US20180228893A1 (en) Combinations and uses thereof
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog